GlassScriptPhysician profile
Yevgeniy Brailovsky
NPI 1356604607
$25,093.34
in general payments reported to CMS, 2019-2025
29 companies · $19K in 2025
The $19K reported for 2025 was more than what 84% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893 · 2020: $480 · 2021: $441 · 2022: $1,593 · 2023: $1,453 · 2024: $1,644 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Food and Beverage: $4,409 · Travel and Lodging: $1,034 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,069.00 |
| Food and Beverage | $4,409.16 |
| Travel and Lodging | $1,033.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $174.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $8,469.35 | 2020-2025 | Amvuttra |
| Pfizer INC. | $6,196.23 | 2021-2025 | |
| Abbott Laboratories | $2,856.41 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Thoratec Heartmate 3, Heartmate Touch |
| Bridgebio Pharma, INC. | $2,721.14 | 2025 | Attruby |
| Astrazeneca Pharmaceuticals LP | $1,386.79 | 2024-2025 | Wainua |
| Impulse Dynamics (USA) INC. | $1,098.54 | 2023-2025 | Optimizer, Optimizer |
| Medtronic Vascular, INC. | $662.83 | 2019 | |
| Novartis Pharmaceuticals Corporation | $291.65 | 2021-2025 | |
| Edwards Lifesciences Corporation | $211.79 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.46 | 2022-2025 | Jardiance |
| Amgen INC. | $124.80 | 2019-2024 | Repatha |
| Novo Nordisk INC | $113.69 | 2023 | Ozempic |
| Daxor Corporation | $113.53 | 2022 | |
| One Lambda, INC. | $100.61 | 2024 | |
| United Therapeutics Corporation | $100.00 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $70.07 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $60.76 | 2021-2022 | |
| Scpharmaceuticals INC. | $58.66 | 2024-2025 | |
| Medtronic, INC. | $53.25 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $51.74 | 2022-2024 | Camzyos, Eliquis |
| Endotronix, INC. | $49.75 | 2023 | Cordella Pulomonary Artery Pressure Sensor |
| Cvrx, INC. | $40.69 | 2024 | Barostim Neo System |
| Kiniksa Pharmaceuticals, LTD. | $28.80 | 2023 | Arcalyst |
| Livanova USA, INC. | $27.48 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.78 | 2023 | Lifevest |
| Merck Sharp & Dohme LLC | $14.58 | 2025 | Winrevair |
| Nuwellis, INC. | $9.96 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yevgeniy Brailovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.